Flavonoid IL-17A inhibitors
The present invention describes compounds according to formula I: and compounds according to formula II: and additional related flavonoid compounds, as well as the use of the compounds in methods for the prevention or treatment of IL-17A-mediated disease in a subject.
1. A method of treating Th17 infiltrated/driven asthma in a subject, consisting of administering to the subject an effective amount of a pharmaceutical composition consisting of compound according to formula I:
wherein R 3 , R 6 , and R 8 are independently selected from —H, —C 1 -C 4 alkyl, —OH, —OMe, and halogen;
R 1 , R 2 , R 4 , and R 5 are —OH and
wherein W is selected from the group consisting of —CH—, —O + —, and —N—;
or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein W is—O + —.
3. The method of claim 1 , wherein the compound is cyanidin.
4. The method of claim 1 , wherein the compound is delphinidin.
5. The method of claim 1 , wherein the compound is administered by intravenous, intramuscular, or subcutaneous injection.
6. The method of claim 1 , wherein the composition is administered by inhalation.